
A second opinion on the need for new warnings on attention deficit hyperactivity disorder (ADHD) drugs from the FDA advisory committee contradicts The Pediatric Advisory Committee recommendation.
A second opinion on the need for new warnings on attention deficit hyperactivity disorder (ADHD) drugs from the FDA advisory committee contradicts The Pediatric Advisory Committee recommendation.
According to recent estimates,chronic medical conditionsaccount for 7 of every 10 deathsin the United States and have been foundto severely limit daily functioning in morethan 1 of 10 Americans, or 25 millionpeople This tremendous disease burdenaccounts for most of the dollars spenton health care annually in the UnitedStates.